Monitoring considerations include: Regular assessment of gastrointestinal tolerability and hydration status Evaluation of any changes in MS symptoms, with low threshold for neurological consultation Glucose monitoring in diabetic patients, with adjustment of other antihyperglycemic agents as needed Periodic assessment of weight loss progress and nutritional adequacy Monitoring for signs of pancreatitis (severe abdominal pain) or gallbladder disease For Wegovy patients, monitoring for depression or suicidal thoughts Patient counseling should address realistic expectations regarding weight loss (typically 15% of body weight over 68 weeks with the 2.4 mg dose plus lifestyle intervention, with less at earlier timepoints), the chronic nature of therapy, and the importance of lifestyle modifications
This guide walks you through how semaglutide fits into HSA and FSA rules, when documentation matters, and how to find options that make purchasing simpler
Semaglutide, marketed as Ozempic, Wegovy, and Rybelsus, is an FDA-approved GLP-1 receptor agonist used to treat type 2 diabetes and support chronic weight management
Have you noticed a reaction on your skin after injecting Wegovy (semaglutide)
Oral presentation presented at ObesityWeek 2024
